Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
102.12
-0.50 (-0.49%)
Aug 12, 2026, 10:23 AM EDT - Market open
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $481.00M in the quarter ending June 30, 2026, with 47.67% growth. This brings the company's revenue in the last twelve months to $1.66B, up 41.15% year-over-year. In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth.
Revenue (ttm)
$1.66B
Revenue Growth
+41.15%
P/S Ratio
6.96
Revenue / Employee
$3,933,187
Employees
423
Market Cap
11.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Exelixis | 2.44B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.21B |
| Corcept Therapeutics | 830.81M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Cytokinetics | 67.67M |
| Praxis Precision Medicines | 7.46M |
HALO News
- 2 days ago - Halozyme price target raised to $95 from $75 at Wells Fargo - TheFly
- 5 days ago - Halozyme price target raised to $105 from $93 at Morgan Stanley - TheFly
- 5 days ago - Halozyme price target raised to $105 from $96 at TD Cowen - TheFly
- 5 days ago - Halozyme price target raised to $95 from $75 at Wells Fargo - TheFly
- 5 days ago - Leerink upgraded Halozyme to Outperform on growth, market leadership - TheFly
- 5 days ago - Halozyme upgraded to Outperform from Market Perform at Leerink - TheFly
- 5 days ago - Halozyme price target raised to $93 from $92 at Citizens - TheFly
- 5 days ago - Halozyme price target raised to $115 from $95 at H.C. Wainwright - TheFly